These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26756335)

  • 1. A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
    Ferguson GD; Delgado M; Plantevin-Krenitsky V; Jensen-Pergakes K; Bates RJ; Torres S; Celeridad M; Brown H; Burnett K; Nadolny L; Tehrani L; Packard G; Pagarigan B; Haelewyn J; Nguyen T; Xu L; Tang Y; Hickman M; Baculi F; Pierce S; Miyazawa K; Jackson P; Chamberlain P; LeBrun L; Xie W; Bennett B; Blease K
    PLoS One; 2016; 11(1):e0145705. PubMed ID: 26756335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
    Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
    J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
    Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
    J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
    Zhang Z; Cao C; Sun S; Xu Q
    Mol Med Rep; 2015 Aug; 12(2):2902-6. PubMed ID: 25955571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
    Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
    Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.
    Pine PR; Chang B; Schoettler N; Banquerigo ML; Wang S; Lau A; Zhao F; Grossbard EB; Payan DG; Brahn E
    Clin Immunol; 2007 Sep; 124(3):244-57. PubMed ID: 17537677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
    Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.
    Scott DL
    Drugs; 2011 Jun; 71(9):1121-32. PubMed ID: 21711059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events.
    Zeng KW; Wang S; Dong X; Jiang Y; Jin HW; Tu PF
    Toxicol Appl Pharmacol; 2014 Mar; 275(3):244-56. PubMed ID: 24486434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JTE-852, a novel spleen tyrosine kinase inhibitor, blocks immunoglobulin G-mediated cellular responses and autoimmune reactions in vivo.
    Kato T; Ohta T; Iwasaki H; Kobayashi H; Matsuo A; Hata T; Matsushita M
    Life Sci; 2017 Dec; 191():166-174. PubMed ID: 29056373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and profiling of a selective and efficacious Syk inhibitor.
    Thoma G; Smith AB; van Eis MJ; Vangrevelinghe E; Blanz J; Aichholz R; Littlewood-Evans A; Lee CC; Liu H; Zerwes HG
    J Med Chem; 2015 Feb; 58(4):1950-63. PubMed ID: 25633741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent Models.
    Hayashi H; Kaneko R; Demizu S; Akasaka D; Tayama M; Harada T; Irie H; Ogino Y; Fujino N; Sasaki E
    J Pharmacol Exp Ther; 2018 Jul; 366(1):84-95. PubMed ID: 29728446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
    Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Tsuji E; Miyazawa K; Misawa K; Ohnota H; Isaji M
    Bioorg Med Chem; 2008 Oct; 16(20):9247-60. PubMed ID: 18823784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
    Bajpai M
    IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
    Kaur M; Singh M; Silakari O
    Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orally bioavailable Syk inhibitors with activity in a rat PK/PD model.
    Thoma G; Veenstra S; Strang R; Blanz J; Vangrevelinghe E; Berghausen J; Lee CC; Zerwes HG
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4642-7. PubMed ID: 26320624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.
    Stump KL; Lu LD; Dobrzanski P; Serdikoff C; Gingrich DE; Dugan BJ; Angeles TS; Albom MS; Ator MA; Dorsey BD; Ruggeri BA; Seavey MM
    Arthritis Res Ther; 2011 Apr; 13(2):R68. PubMed ID: 21510883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.
    Choi JS; Hwang HJ; Kim SW; Lee BI; Lee J; Song HJ; Koh JS; Kim JH; Lee PH
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4441-6. PubMed ID: 26384287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs.
    Lee SJ; Choi JS; Han BG; Kim HS; Song HJ; Lee J; Nam S; Goh SH; Kim JH; Koh JS; Lee BI
    FEBS J; 2016 Oct; 283(19):3613-3625. PubMed ID: 27504936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction.
    Moy LY; Jia Y; Caniga M; Lieber G; Gil M; Fernandez X; Sirkowski E; Miller R; Alexander JP; Lee HH; Shin JD; Ellis JM; Chen H; Wilhelm A; Yu H; Vincent S; Chapman RW; Kelly N; Hickey E; Abraham WM; Northrup A; Miller T; Houshyar H; Crackower MA
    Am J Respir Cell Mol Biol; 2013 Dec; 49(6):1085-92. PubMed ID: 23889698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.